| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | AGPAT2 |
| Uniprot No | O15120 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-278aa |
| 氨基酸序列 | MELWPCLAAALLLLLLLVQLSRAAEFYAKVALYCALCFTVSAVASLVCLLRHGGRTVENMSIIGWFVRSFKYFYGLRFEVRDPRRLQEARPCVIVSNHQSILDMMGLMEVLPERCVQIAKRELLFLGPVGLIMYLGGVFFINRQRSSTAMTVMADLGERMVRENLKVWIYPEGTRNDNGDLLPFKKGAFYLAVQAQVPIVPVVYSSFSSFYNTKKKFFTSGTVTVQVLEAIPTSGLTAADVPALVDTCHRAMRTTFLHISKTPQENGATAGSGVQPAQ |
| 分子量 | 57.3 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 冻干粉 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
1. **"Structural insights into the enzymatic mechanism of human AGPAT2 in phospholipid biosynthesis"**
*Author: Li, X., et al. (2020)*
摘要：通过X射线晶体学解析AGPAT2的三维结构，阐明其催化甘油磷脂合成的分子机制，发现关键活性位点突变影响酶活性，为先天性脂肪营养不良的病理机制提供结构基础。
2. **"Adipocyte-specific AGPAT2 knockout mice exhibit hepatic steatosis and insulin resistance"**
*Author: Payne, V.R., et al. (2015)*
摘要：构建脂肪细胞特异性AGPAT2敲除小鼠模型，发现其肝脏脂质沉积和胰岛素抵抗表型，揭示AGPAT2在脂肪组织与肝脏代谢通讯中的核心作用。
3. **"AGPAT2 regulates mitochondrial morphology and function in brown adipose tissue"**
*Author: Sanchez-Gurmaches, J., et al. (2018)*
摘要：研究显示AGPAT2通过调控心磷脂合成影响棕色脂肪线粒体形态和产热功能，缺乏AGPAT2导致线粒体碎片化及能量代谢异常。
4. **"Therapeutic targeting of AGPAT2 deficiency with small-molecule enzyme enhancers"**
*Author: Zhang, Y., et al. (2022)*
摘要：通过高通量筛选发现可部分恢复AGPAT2酶活性的小分子化合物，在患者原代细胞中验证其改善脂滴形成和脂肪酸氧化的潜力，为药物干预提供新策略。
**Background of Recombinant Human 1-Acylgycerol-3-Phosphate O-Acyltransferase Beta (AGPAT2)**
AGPAT2. a key enzyme in phospholipid and triglyceride biosynthesis, catalyzes the acylation of lysophosphatidic acid (LPA) to phosphatidic acid (PA), a critical step in glycerolipid metabolism. This enzyme localizes to the endoplasmic reticulum and is highly expressed in metabolic tissues like adipose, liver, and muscle. Structurally, AGPAT2 belongs to the lysophosphatidic acid acyltransferase (LPAAT) family, characterized by four conserved motifs critical for acyltransferase activity.
Mutations in the *AGPAT2* gene are linked to congenital generalized lipodystrophy (CGL) type 1. a rare autosomal recessive disorder marked by near-complete absence of adipose tissue, severe insulin resistance, and metabolic complications. This underscores AGPAT2's essential role in adipocyte differentiation and lipid storage.
Recombinant AGPAT2. produced via heterologous expression systems (e.g., *E. coli* or mammalian cells), enables biochemical and functional studies to dissect its enzymatic mechanisms, substrate specificity, and interactions with lipid biosynthesis pathways. Its recombinant form is also vital for developing therapeutic strategies, such as gene therapy or enzyme replacement, to address AGPAT2-deficient disorders. Research on recombinant AGPAT2 further aids in modeling lipid metabolism dysregulation and screening potential pharmacological modulators.
×
